Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Nuvo Research Inc -- Ignore unavailable to you. Want to Upgrade?

To: jef saunders who wrote (8600)	1/30/2002 11:39:56 PM
From: axial	Respond to of 14101

Hi Jef - Assuming you've seen all the old stuff on WF10, WF-10, TCDO, tetrachlorodecaoxide, tetrachlorodecaoxygen, etc. wf10.com I have found nothing new. P3 allowed for HIV-associated lymphoma... Exclusion Criteria: Patients who meet any of the following exclusion criteria will be ineligible for the study: Patient has any malignancy other than HIV-associated lymphoma, basal cell or squamous cell carcinoma of the skin, nonsystemic Kaposi's sarcoma, or carcinoma in situ of the cervix... _________________________________________ I am aware that WF10 is still available by Special Application, and is being used, as we speak, in the treatment of HIV and cancer, in Canada. The anecdotal information that I have indicates that use of WF10 earlier in the disease process has had good results. WF10 is being used in treatment of autoimmune disorders, as well. I am informed that this information will likely be made public within a few weeks, but that is not a certainty. I want to be clear that this information is not derived from trials. Regards, Jim